The research presents a catch-bond engineering method to overcome T-cell tolerance to tumor self-antigens.[1] Catch-bonds are special bonds that strengthen under mechanical stress, improving the adhesion of T-cells to tumor cells.[1] This technology enables T-cells to more effectively recognize and attack tumor cell-expressed self-antigens that normally induce immune tolerance.[1] The study shows that engineered T-cells overcome physical and immunological barriers in the tumor microenvironment of solid tumors.[1][2] The main finding is an improvement in T-cell infiltration and function, leading to a more robust antitumor response without loss of specificity.[1] The method combines synthetic biology with the principles of adhesive molecules to increase the effectiveness of CAR-T and TCR-T therapies.[1][7] The results suggest potential for clinical applications in the treatment of solid tumors resistant to standard immunotherapy.[1]